Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Momordica Charantia Extract vs DHP+PQ in Uncomplicated Falciparum Malaria
NCT05829187Phase 2Completed
- Start
- Nov 2022
- Primary completion
- Dec 2022
- Modality
- Botanical Extract
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of momordica charantia extract in Plasmodium falciparum malaria (2 arms). Primary endpoint: development of sexual and asexual stages of Plasmodium falciparum at 28 days. Started Nov 2022; status: completed.
02
Drugs
momordica charantia extract
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT05829187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05829187.